Retatrutide is an innovative triple receptor agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptors. It is mainly used to treat type 2 diabetes and obesity, significantly improving blood sugar control and promoting weight loss through multiple mechanisms. Clinical studies have shown that Retatrutide performs well in blood sugar reduction, weight loss and metabolic regulation, providing a breakthrough option for the treatment of metabolic diseases.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H - Tyr - Aib - Glu - Gly - Thr - Phe - Thr - Ser - Asp - Tyr - Ser - Ile - Aib - Leu - Asp - Lys - Ile - Ala - Gln - {20diacid - gamma - Glu - (AEEA)2 - Lys}-Ala - Phe - Val - Gln - Trp - Leu - Ile - Ala - Gly - Gly - Pro - Ser - Ser - Gly - Ala - Pro - Pro - Pro - Ser - NH2 |
Single letter sequence |
HYAE(20diacid - gamma - Glu - (AEEA)2 - K)AFVQWLIAGGPS SGA PPPS - NH2 |
CAS Number |
2023788-19-2 |
Molecular formula |
C221H342N46O68 |
Molecular weight |
4731.33 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |